Patient Characteristics, Persistence to Treatment and Outcome Events in Patients Treated With Ticagrelor 60 mg After Myocardial Infarction in Real-world Clinical Practice

Inclusion Criteria: Primary Analysis Population: * Hospitalisation with a primary diagnosis of MI during the eligibility period * Ticagrelor cohort: A first prescription of ticagrelor 60 mg after the most recent hospitalisation with a primary diagnosis of MI. * Non-ticagrelor cohort: A prescription of clopidogrel, prasugrel or ticlopidine, or no prescription for any of these medications, at a comparable timepoint relative to their MI as for the ticagrelor cohort Secondary Analysis Population: * The qualifying prescription 12-36 months after a hospitalisation with a primary diagnosis of MI and treatment with an ADP receptor antagonist (clopidogrel, prasugrel, ticagrelor 90 mg, ticlopidine) ≤12 months prior to the qualifying prescription, or the qualifying prescription 12-24 months after a hospitalisation with a primary diagnosis of MI AND * Age ≥50 years * At least one of the following risk factors: * Age ≥ 65 years * Diabetes mellitus requiring medication * A second prior MI * Evidence of multivessel coronary artery disease * Chronic non-end-stage renal dysfunction Exclusion Criteria: Applicable to the Primary and Seconday Analysis Populations: * Dies, emigrates, or disenrolls from the database (where applicable) prior to the ticagrelor approval date. * Ineligibility for ticagrelor use (restricted to the conditions possible to capture within the data sources)-one or more of the following: * Concomitant use of an anticoagulant * Prior ischaemic stroke …